These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38142123)

  • 1. Precision dosing of venlafaxine during pregnancy: a pharmacokinetics modelling approach.
    Alenezi M; Badhan RKS
    J Pharm Pharmacol; 2024 Jan; 76(2):122-137. PubMed ID: 38142123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.
    Almurjan A; Macfarlane H; Badhan RKS
    J Pharm Pharmacol; 2020 Aug; 72(8):1049-1060. PubMed ID: 32346890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising Fluvoxamine Maternal/Fetal Exposure during Gestation: A Pharmacokinetic Virtual Clinical Trials Study.
    Burhanuddin K; Badhan R
    Metabolites; 2022 Dec; 12(12):. PubMed ID: 36557319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
    Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study.
    Almurjan A; Macfarlane H; Badhan RKS
    Biopharm Drug Dispos; 2021 Jun; 42(6):252-262. PubMed ID: 33851424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.
    Badaoui S; Hopkins AM; Rodrigues AD; Miners JO; Sorich MJ; Rowland A
    AAPS J; 2021 Jan; 23(1):15. PubMed ID: 33404848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study.
    Badhan RKS; Gittins R
    J Subst Abuse Treat; 2021 Nov; 130():108521. PubMed ID: 34118695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
    Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
    Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis.
    Lin XQ; Wang P; Cai WK; Xu GL; Yang M; Zhou MD; Sun M; He F; He GH
    Pharmacopsychiatry; 2019 Sep; 52(5):222-231. PubMed ID: 30485867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
    Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
    Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry.
    Berm E; Kok R; Hak E; Wilffert B
    Pharmacopsychiatry; 2016 Sep; 49(5):186-190. PubMed ID: 27101231
    [No Abstract]   [Full Text] [Related]  

  • 13. Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.
    Linares OA; Fudin J; Daly AL; Boston RC
    Clin J Pain; 2015 Dec; 31(12):1026-35. PubMed ID: 25621429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
    Kringen MK; Bråten LS; Haslemo T; Molden E
    J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
    McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
    Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
    Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
    J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational study of Venlafaxine and CYP2D6 in clinical practice.
    Rolla R; Gramaglia C; Dalò V; Ressico F; Prosperini P; Vidali M; Meola S; Pollarolo P; Bellomo G; Torre E; Zeppegno P
    Clin Lab; 2014; 60(2):225-31. PubMed ID: 24660534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.
    Fukuda T; Yamamoto I; Nishida Y; Zhou Q; Ohno M; Takada K; Azuma J
    Br J Clin Pharmacol; 1999 Apr; 47(4):450-3. PubMed ID: 10233212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Zubiaur P; Koller D; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2021 Dec; 60(12):1569-1582. PubMed ID: 34125422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.
    Fukuda T; Nishida Y; Zhou Q; Yamamoto I; Kondo S; Azuma J
    Eur J Clin Pharmacol; 2000 May; 56(2):175-80. PubMed ID: 10877013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.